CL2015001279A1 - Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. - Google Patents
Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.Info
- Publication number
- CL2015001279A1 CL2015001279A1 CL2015001279A CL2015001279A CL2015001279A1 CL 2015001279 A1 CL2015001279 A1 CL 2015001279A1 CL 2015001279 A CL2015001279 A CL 2015001279A CL 2015001279 A CL2015001279 A CL 2015001279A CL 2015001279 A1 CL2015001279 A1 CL 2015001279A1
- Authority
- CL
- Chile
- Prior art keywords
- diseases
- urat
- hyperuricemia
- gout
- hypertension
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012250661 | 2012-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001279A1 true CL2015001279A1 (es) | 2015-06-26 |
Family
ID=50731196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001279A CL2015001279A1 (es) | 2012-11-14 | 2015-05-12 | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. |
Country Status (36)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170144987A1 (en) * | 2014-05-13 | 2017-05-25 | Teijin Pharma Limited | Novel crystalline polymorphs of pyridine derivative and method for producing the same |
| DK3144306T3 (en) * | 2014-05-13 | 2018-01-02 | Teijin Pharma Ltd | pyrazine |
| EP3429355B1 (de) * | 2016-03-15 | 2020-02-05 | Bayer CropScience AG | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| JP6724246B2 (ja) * | 2016-05-23 | 2020-07-15 | シーストーン ファーマシューティカル （スージョウ） カンパニー リミテッド | チオフェン化合物、その合成方法及び医療における応用 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| WO2018130437A1 (de) | 2017-01-10 | 2018-07-19 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| JP7098630B2 (ja) | 2017-01-10 | 2022-07-11 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロサイクレン誘導体 |
| CN108658879A (zh) * | 2017-03-29 | 2018-10-16 | 天津药物研究院有限公司 | 一种urat1抑制剂及其制备方法和用途 |
| CN109251184B (zh) * | 2017-07-13 | 2021-06-15 | 浙江海正药业股份有限公司 | 一种2-三氟甲基苯磺酰胺类衍生物的医药用途 |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TWI820231B (zh) | 2018-10-11 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於製備經取代咪唑衍生物之方法 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| EP4055010A1 (de) | 2019-11-07 | 2022-09-14 | Bayer Aktiengesellschaft | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
| CN116033828B (zh) | 2020-07-02 | 2025-05-16 | 拜耳公司 | 作为害虫防治剂的杂环衍生物 |
| CN114315729B (zh) * | 2021-12-09 | 2024-01-26 | 大连理工大学 | 1-苄基-2，4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用 |
| WO2025026738A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1599032A (en) * | 1977-03-04 | 1981-09-30 | May & Baker Ltd | Imidazole derivatives having herbicidal activity |
| JPS5671073A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| PL149675B1 (pl) * | 1986-03-10 | 1990-03-31 | Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5 | |
| US4770689A (en) | 1986-03-10 | 1988-09-13 | Janssen Pharmaceutica N.V. | Herbicidal imidazole-5-carboxylic acid derivatives |
| US4851424A (en) | 1986-06-06 | 1989-07-25 | Ciba-Geigy Corporation | 1-Phenyl-lower alkyl-imidazole 4- or 5-carboxamide compounds which are useful in the treatment of epilepsy |
| DD260928A5 (de) * | 1986-06-06 | 1988-10-12 | Ciba-Geigy Ag,Ch | Verfahren zur herstellung neuer aralkylimidizolderivate |
| JPH08119936A (ja) | 1994-10-18 | 1996-05-14 | Fujisawa Pharmaceut Co Ltd | 複素環式誘導体 |
| IT1295405B1 (it) | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
| KR20030031132A (ko) * | 2000-07-28 | 2003-04-18 | 스미또모 세이야꾸 가부시키가이샤 | 피롤 유도체 |
| EP1362854B1 (en) | 2001-02-22 | 2007-10-31 | Teijin Pharma Limited | Benzo[b[thiophene derivatives and process for producing the same |
| AU2003902828A0 (en) * | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| ES2513390T3 (es) * | 2007-11-27 | 2014-10-27 | Ardea Biosciences, Inc. | Nuevos compuestos y composiciones, y métodos de uso |
| WO2009148599A1 (en) * | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| BRPI0918586A2 (pt) * | 2008-09-04 | 2015-12-01 | Ardea Biosciences Inc | compostos, composições e métodos de uso dos mesmos para a modulação dos níveis de ácido úrico |
| JP2010202575A (ja) * | 2009-03-03 | 2010-09-16 | Takeda Chem Ind Ltd | 複素環化合物 |
| US8765973B2 (en) * | 2009-07-10 | 2014-07-01 | The General Hospital Corporation | Etomidate analogues that do not inhibit adrenocortical steroid synthesis |
| CN102035579B (zh) * | 2009-09-28 | 2014-09-03 | 夏普株式会社 | 信息反馈方法和用户设备 |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| JP5485811B2 (ja) * | 2010-06-23 | 2014-05-07 | 株式会社ジャパンディスプレイ | 双方向シフトレジスタ、及びこれを用いた画像表示装置 |
| US8796268B2 (en) * | 2010-08-11 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
-
2013
- 2013-11-13 US US14/441,074 patent/US9637469B2/en not_active Expired - Fee Related
- 2013-11-13 TW TW102141292A patent/TWI666205B/zh not_active IP Right Cessation
- 2013-11-13 PT PT138547146T patent/PT2944633T/pt unknown
- 2013-11-13 SG SG11201503770VA patent/SG11201503770VA/en unknown
- 2013-11-13 CN CN201380059519.0A patent/CN104797570B/zh not_active Expired - Fee Related
- 2013-11-13 UA UAA201505767A patent/UA117359C2/uk unknown
- 2013-11-13 DK DK13854714.6T patent/DK2944633T3/en active
- 2013-11-13 AU AU2013345894A patent/AU2013345894B2/en not_active Ceased
- 2013-11-13 HU HUE13854714A patent/HUE037736T2/hu unknown
- 2013-11-13 JP JP2014547007A patent/JP5774238B2/ja not_active Expired - Fee Related
- 2013-11-13 RS RS20180390A patent/RS57090B1/sr unknown
- 2013-11-13 WO PCT/JP2013/080706 patent/WO2014077285A1/ja not_active Ceased
- 2013-11-13 CA CA2891408A patent/CA2891408A1/en not_active Abandoned
- 2013-11-13 SM SM20180322T patent/SMT201800322T1/it unknown
- 2013-11-13 SG SG10201705852PA patent/SG10201705852PA/en unknown
- 2013-11-13 MA MA38078A patent/MA38078B1/fr unknown
- 2013-11-13 NO NO13854714A patent/NO2944633T3/no unknown
- 2013-11-13 RU RU2015122698A patent/RU2640588C2/ru active
- 2013-11-13 MX MX2015003672A patent/MX2015003672A/es unknown
- 2013-11-13 EP EP18152142.8A patent/EP3339302A1/en not_active Withdrawn
- 2013-11-13 PL PL13854714T patent/PL2944633T3/pl unknown
- 2013-11-13 AR ARP130104172A patent/AR093468A1/es unknown
- 2013-11-13 ES ES13854714T patent/ES2662444T3/es active Active
- 2013-11-13 PE PE2015000616A patent/PE20150974A1/es not_active Application Discontinuation
- 2013-11-13 KR KR1020157008457A patent/KR20150082194A/ko not_active Withdrawn
- 2013-11-13 CN CN201710933918.5A patent/CN107721931A/zh active Pending
- 2013-11-13 NZ NZ708031A patent/NZ708031A/en not_active IP Right Cessation
- 2013-11-13 BR BR112015010977A patent/BR112015010977A2/pt not_active Application Discontinuation
- 2013-11-13 EP EP13854714.6A patent/EP2944633B1/en active Active
- 2013-11-13 ME MEP-2018-91A patent/ME03016B/me unknown
- 2013-11-13 LT LTEP13854714.6T patent/LT2944633T/lt unknown
- 2013-11-13 SI SI201330943T patent/SI2944633T1/en unknown
- 2013-11-13 HR HRP20180451TT patent/HRP20180451T1/hr unknown
-
2015
- 2015-01-16 JP JP2015007229A patent/JP6293068B2/ja not_active Expired - Fee Related
- 2015-04-30 IL IL238539A patent/IL238539A/en not_active IP Right Cessation
- 2015-05-08 PH PH12015501037A patent/PH12015501037A1/en unknown
- 2015-05-12 CL CL2015001279A patent/CL2015001279A1/es unknown
- 2015-05-13 ZA ZA2015/03322A patent/ZA201503322B/en unknown
- 2015-05-13 SA SA515360431A patent/SA515360431B1/ar unknown
- 2015-12-17 IL IL243193A patent/IL243193A0/en unknown
-
2017
- 2017-03-22 US US15/466,088 patent/US20170190694A1/en not_active Abandoned
- 2017-07-07 AU AU2017204665A patent/AU2017204665A1/en not_active Abandoned
-
2018
- 2018-04-10 CY CY20181100389T patent/CY1120127T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2016001889A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1. | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
| DOP2015000274A (es) | Compuestos químicos | |
| DOP2016000271A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
| CR20140223A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| DK3330259T3 (da) | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne | |
| CL2015000706A1 (es) | Compuestos derivados biciclicos conteniendo nitrogeno y sus sales; su proceso de obtencion; composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de estados patologicos renales, hepaticos, inflamatorios, del sistema nervioso, enfermedades fibroticas y rechazo agudo y cronico del trasplante de organos. | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| CL2015000615A1 (es) | Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau. | |
| MX2016009013A (es) | Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4). | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| HUE060743T2 (hu) | Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| CL2016001283A1 (es) | Derivado de urea o sal farmacológicamente aceptable del mismo | |
| CL2014002257A1 (es) | Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer. |